Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma
NL-OMON59746Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab plus ipilimumab with Sunitinib monotherapy (2 arms). Primary endpoints: overall survival and progression-free survival. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON59746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59746.